Unicycive Therapeutics Announces Resubmission of New Drug Application for Oxylanthanum Carbonate
MOUNTAIN VIEW, Calif., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (“Unicycive” or the “Company”) NASDAQ:UNCY, a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced the resubmission of its New Drug Application (NDA) for oxy…